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Abstract
Cross-reactivity of Fusarium species with serum galactomannan antigen (GMI) test has been observed. We sought to
evaluate if GMI could help to early diagnose invasive fusariosis and to monitor treatment response. We reviewed the records
of all patients with invasive fusariosis between 2008 and 2012 in three Brazilian hospitals. We selected patients who had at
least 1 GMI test within 2 days before or after the date of the first clinical manifestation of fusariosis, and analyzed the
temporal relationship between the first positive GMI test and the date of the diagnosis of invasive fusariosis, and the kinetics
of GMI in relation to patients’ response to treatment. We also selected 18 controls to determine the sensitivity and
specificity of the test. Among 18 patients, 15 (83%) had at least one positive GMI (median 4, range 1–15). The sensitivity and
specificity of was 83% and 67%, respectively. GMI was positive before the diagnosis of invasive fusariosis in 11 of the 15
cases (73%), at a median of 10 days (range 3–39), and after the diagnosis in 4 cases. GMI became negative in 8 of the 15
patients; 3 of these 8 patients (37.5%) were alive 90 days after the diagnosis of fusariosis compared with 2 of 7 (29%) who
did not normalize GMI (p = 1.0). GMI is frequently positive in invasive fusariosis, and becomes positive before diagnosis in
most patients. These findings may have important implications for the choice of antifungal therapy in settings with high
prevalence of invasive fusariosis.
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Introduction
The management of invasive aspergillosis has greatly improved
with the introduction of antigen detection [1]. Serum galacto-
mannan antigen (GMI) testing is an important tool for both
diagnosis and outcome evaluation of invasive aspergillosis [2–5].
Although GMI is considered specific for Aspergillus species, cross-
reactivity with other fungi, including moulds and dimorphic fungi,
has been occasionally reported [6–9]. Recently, two papers
reported cross-reactivity of GMI with Fusarium species. One study
presented a case of invasive fusariosis caused by Fusarium
verticillioides in a hematopoietic cell transplant (HCT) recipient in
which serum GMI was positive seven days before the diagnosis of
fusariosis [10]. The other study reported 9 out of 11 patients with
hematologic diseases and invasive fusariosis with positive GMI
tests. The temporal relationship between GMI positivity and the
diagnosis of invasive fusariosis was not reported [11].
In the present study we report 18 cases of invasive fusariosis
diagnosed in hematologic patients who were actively monitored
with serial serum GMI, 15 of which had positive GMI tests. We
analyzed the performance of GMI, the temporal relationship
between GMI positivity and the diagnosis of fusariosis, and the
kinetics of GMI after treatment.
Patients and Methods
This is a retrospective study conducted in three tertiary care
hospitals in Brazil. We reviewed all cases of invasive fusariosis
diagnosed in the three institutions since the introduction of active
monitoring of high-risk hematologic patients with serial (at least 2
times per week, starting on admission) serum GMI testing. Entry
criteria were: to have a diagnosis of proven or probable invasive
fusariosis according to the revised EORTC/MSG diagnostic
criteria [12], to have at least one GMI test performed within two
days before or after the date of the first clinical manifestation
attributed to invasive fusariosis, and no isolation of Aspergillus
species from any biological material. The study was approved by
the institutions’ ethical committees, and a waiver of the need for
written informed consent was granted, because of the observa-
tional nature of the study: Comite de Etica em Pesquisa do
Hospital Universita´rio Clementino Fraga Filho and Comite de
Etica em Pesquisa da Unifesp/EPM.
Patients were managed according predefined standards of care
at each institution. Active monitoring of patients at risk for invasive
aspergillosis with serial serum GMI started in 2008, and consisted
of GMI testing 2–3 times per week during periods at risk, starting
on admission. In case of fever and neutropenia, empiric antibiotic
therapy with a beta lactam was started after collection of blood
cultures. Additional blood cultures were obtained in case of
persistence or recurrence of fever, or at the discretion of the
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attending clinician. A diagnostic-driven antifungal approach was
given to patients with persistent fever, consisting of active
monitoring with serial serum GMI and chest and sinuses
computed tomography (CT) scans. Serum GMI testing was
performed according to the manufacturer’s instructions (Platelia
Aspergillus EIA; Bio-Rad, Redmond, WA). A positive GMI test
was defined by an optical density [OD] index$0.5. Blood cultures
were processed by automated systems (either Bactec or BacTA-
lert).
We reviewed patients’ charts, results of GMI, blood cultures,
histopathology, and results of direct exam and culture of different
biological materials that served the basis for the diagnosis of
invasive fusariosis. Information from patients included demo-
graphics (age, gender), underlying hematologic disease, recent
treatment for the underlying disease, presence and duration of
neutropenia, receipt of corticosteroids, antifungal prophylaxis,
date of the first clinical manifestation attributed to invasive
fusariosis, clinical presentation, source of diagnosis, date in which
the diagnosis was established, treatment and outcome. We
analyzed the temporal relationship between the first positive
GMI test and the date of the first clinical manifestation and the
date of diagnosis of invasive fusariosis, as well as the kinetics of
GMI in relation to patients’ response to treatment.
Neutropenia was defined as an absolute neutrophil count (ANC)
,500/mm3. Disseminated fusariosis was defined as involvement
of .1 non-contiguous organs. Cases of fungemia were not defined
as disseminated disease unless another organ was involved (e.g.
skin, lung or sinuses).
In order to analyze the performance of GMI in the diagnosis of
invasive fusariosis, we selected one control for each case and
calculated the sensitivity and specificity of the test. Controls had to
have received similar underlying diseases and/or treatment as
cases, to have had at least two GMI tests performed per week, and
no invasive fungal disease diagnosed in the period. The controls
were selected blindly for the results of GMI, and a careful review
of patients’ charts was performed to ascertain that no invasive
fungal disease was diagnosed in that period. We also evaluated the
best GMI cutoff value constructing the area under the receiver
operating characteristic (ROC) curve. Categorical variables were
compared using Fisher exact test and continuous variables were
compared using the Wilcoxon test.
Results
Between 2008 and 2012, 25 cases of invasive fusariosis were
diagnosed in the three institutions. Seven cases were excluded;
four because no GMI tests were performed in the period, and
three because the closest GMI test was .2 days from the date of
the first clinical manifestation of invasive fusariosis. The main
characteristics of the remaining 18 cases are shown in Table 1.
Acute myeloid leukemia (AML) was the most frequent underlying
condition (6 patients); there were eight HCT recipients (7
allogeneic and 1 autologous). All but one patient was neutropenic.
Invasive fusariosis was classified as disseminated in 13 patients
(72%), fungemia and cutaneous localized infection in two patients
each, and arthritis in one patient. Skin involvement was present in
13 patients, pneumonia in 14 (11 of whom with bilateral
involvement), sinusitis in four, and arthritis and central nervous
system involvement in one patient each. Overall, blood cultures
were positive in six patients. Species identification was available in
11 cases: Fusarium solani species complex (FSSC) in eight and
Fusarium oxysporum species complex (FOSC) in three patients.
The diagnosis was made by culture + histopathology in 10 cases,
culture alone in seven cases, and histopathology alone in one case.
As shown in Table 2, the primary source of diagnosis was skin (10
patients), followed by blood (5 patients). The fastest way of
reaching a presumptive diagnosis was by direct exam of a skin
biopsy (7 patients) or other biological material (sinus aspirate and
bronchoalveolar lavage, one patient each). In these cases, the
finding of hyaline hyphae in the direct exam was reached just a
few hours after the procedure performed for obtaining the
samples, and prompted the immediate initiation of antifungal
treatment. The median time to positivity of blood culture was
three days (range 1–4). In two cases the diagnosis was established
.1 week after the diagnostic procedure; in both the direct exam of
a skin biopsy was negative and the diagnosis was established by
histopathology or culture + histopathology.
All 18 patients received treatment. The most frequent drug used
as primary therapy was voriconazole (8 patients), followed by
deoxycholate amphotericin B (4 patients). The remaining six
patients received combination therapy (lipid amphotericin B plus
voriconazole and deoxycholate amphotericin B plus voriconazole,
3 patients each). The 30-day and 90-day survival was 50% and
33%, respectively.
The median number of GMI tests per patient was 13.5 (range
2–24). Fifteen of the 18 patients (83%) had at least one positive
GMI test: all three cases caused by FOSC, seven of 10 caused by
FSSC, and three of five of Fusarium sp. Among the 15 patients with
positive GMI, the median number of positive GMI tests per
patient was 4 (range 1–15), and the median value of the first
positive and peak GMI was 0.778 (range 0.506–1.915) and 0.969
(0.506–6.382), respectively. One of the three patients with negative
GMI had 10 GMI tests performed while on voriconazole
prophylaxis, which had been given since 28 days before the
diagnosis of fusariosis. The other two patients had seven and 13
negative GMI tests, respectively. They were neutropenic, and had
disseminated disease with bilateral lung involvement and sinusitis
(1 patient) and metastatic skin lesions (1 patient). We did not find
any difference between the 15 patients with positive GMI and the
three with negative GMI tests.
Table 1. Characteristics of 18 patients with invasive fusariosis.
Characteristics
Gender male: female 16:2
Age (years), median (range) 46 (10–69)
Underlying disease
Acute myeloid leukemia 6
Acute lymphoid leukemia 4
Multiple myeloma 2
Other* 6
Recent treatment for the underlying disease
Chemotherapy 9
Allogeneic HCT 7
Autologous HCT 1
No treatment 1
Neutropenia 17
Receipt of corticosteroids** 7
*Other underlying disease (1 case each): non-Hodgkin’s lymphoma, chronic
myeloid leukemia, aplastic anemia, myelodysplasia, chronic lymphoid leukemia,
and myelofibrosis
HCT= hematopoietic cell transplantation
**Within 4 weeks before the diagnosis of invasive fusariosis.
doi:10.1371/journal.pone.0087784.t001
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We analyzed the timing of GMI positivity related to the first
clinical manifestation attributed to fusariosis and to the diagnosis
of fusariosis (Table 2). GMI was positive before the first clinical
manifestation of fusariosis in eight of the 15 patients with positive
GMI (53%), at a median of 8 days (range 1–14), on the same day
in one case, and after the first clinical manifestation in the
remaining six cases, at a median of 6.5 days (range 2––15).
Likewise, GMI was positive before the final diagnosis of invasive
fusariosis in 11 of the 15 cases (73%), at a median of 10 days (range
3–39), and after the diagnosis in the remaining four cases (2, 4, 6
and 8 days after). The 11 patients with positive GMI before the
diagnosis of invasive fusariosis had a median of 2 positive tests
before diagnosis (range 1–7), with five patients presenting $4
positive tests before the diagnosis. The patients with positive GMI
39 and 25 days before the diagnosis of fusariosis had 4 and 5
negative tests during this period, respectively. Both were receiving
anti-mould active antifungal agents in this period (Table 2).
In eight of the 15 patients with positive GMI the test became
negative, at a median of 14 days from the first positive test (range
1–25). Three of these eight patients (37.5%) were alive 90 days
after the diagnosis of fusariosis compared with two of seven (29%)
who did not normalize GMI (p = 1.0). Similarly, there was no
correlation between fast (within 7 days from first positive) GMI
normalization and 90-day outcome (1 of 3 alive with fast
normalization vs. 4 of 12 who normalized later or did not
normalize GMI).
Cases and controls were similar regarding age, gender,
underlying disease and its treatment, and presence and duration
of neutropenia. The median number of GMI tests performed was
higher in cases than in controls (13.5, range 2–24 vs. 6.5, range 3–
14, p= 0.003). Six controls (33%) had positive GMI (median of 1
positive test, range 1–3). Considering the cutoff of 0.5, the
sensitivity and specificity of GMI was 83% and 67%, respectively.
The best cutoff value according to the ROC curve was 0.518, with
an area under the curve of 0.738 (95% confidence interval 0.557–
0.919), sensitivity of 79% and specificity of 72%.
Discussion
In this study we observed that GMI is frequently positive in
patients with invasive fusariosis (15 of 18, 83%), with .1 positive
test per episode (median of 4). We also observed that in most
patients the test was positive before the diagnosis (73%) or even the
first clinical manifestation attributed to invasive fusariosis. The
sensitivity of the test was good, and the best cutoff was close to the
0.5 value defined for invasive aspergillosis. Finally, there was no
correlation between GMI kinetics and the outcome.
The GMI test is an ELISA-based test that uses the rat
monoclonal antibody EB-A2. The antibody recognizes a galacto-
mannan epitope that contains galactofuranose, a polysaccharide
present in various moulds, including Fusarium species [13,14].
Therefore, cross-reactivity of the GMI test with other fungi may
occur, Occasional cases of fusariosis with positive GMI had been
Table 2. Source of diagnosis and temporal relationship between the first positive galactomannan and diagnosis in 18 patients
with invasive fusariosis.
Patient
Primary source of
diagnosis Direct exam Culture Histopathology
Time (days) from
procedure to diagnosis
Time (days) from 1st serum
GMI to diagnosis
1 Skin Positive Positive Positive 0 216*
2 Skin Positive Positive Positive 0 +4
3 Skin Positive Positive Positive 0 21
4 Skin Positive Positive Positive 0 213
5 Skin Positive Positive Positive 0 214
6 Skin Positive Positive Positive 0 28
7 Skin Positive Positive Positive 0 26
8 Skin NP Positive Positive 8 Negative
9 Skin Negative Positive Positive 5 +8
10 Skin Negative Negative Positive 11 Negative
11 Blood NA Positive NA 1 225**
12 Blood NA Positive NA 3 23
13 Blood NA Positive NA 4 210
14 Blood NA Positive NA 3 +2
15 Blood NA Positive NA 3 +6
16 Sinus aspirate Positive Positive NA 0 Negative
17 Synovial fluid Negative Positive NA 4 239***
18 Bronchoalveolar lavage Positive Positive Positive (skin) 0 210
GMI = galactomannan antigen; NP = not performed; NA= not applicable; the signal (+) means that serum galactomannan antigen became positive after the diagnosis
of invasive fusariosis, and the signal (2) means that serum galactomannan antigen became positive before the diagnosis of invasive fusariosis
*This patient had 4 positive GMI tests before the first clinical manifestation of fusariosis and 7 positive tests before the diagnosis.
**This patient had 2 positive GMI tests 25 days before the diagnosis of fusariosis, and another positive test on the day of a positive blood culture for Fusarium. During
this 25-day period the patient received anidulafungin for the treatment of a candidemia, and had 5 negative GMI tests, with values .0.4.
***This patient had 3 positive GMI tests while neutropenic, with focal ground-glass infiltrates in the left lung. Neutropenia resolved and the patient received
posaconazole prophylaxis for the subsequent cycle of chemotherapy. Eleven days after the last positive GMI test he complained of pain and edema in the left knee. The
edema increased when he became neutropenic, and a puncture was performed 25 days after the first symptom. During this period 5 GMI tests were negative.
doi:10.1371/journal.pone.0087784.t002
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reported [15]. In a recent study, 12 clinical isolates of different
species of Fusarium were tested for the reactivity with GMI. All
Fusarium isolates produced positive reactions, with GMI values
ranging from 1.15 to 4.14. In addition, among 11 patients with
hematologic malignancies who developed invasive fusariosis (8
proven and 3 probable, 5 due to Fusarium proliferatum, 3 due to F.
verticillioides, 2 due to F. oxysporum and 1 due to FSSC) nine had
positive GMI tests, with values ranging from 0.53 to 7.7. No
information about the time of occurrence of GMI positivity related
to the diagnosis of invasive fusariosis or the kinetics of GMI in
treated patients was provided. The authors concluded that GMI
may be useful for the diagnosis and assessment of treatment
response among patients with invasive fusariosis [11]. The
temporal relationship with GMI and the diagnosis of fusariosis
was reported recently in an allogeneic HCT recipient. The patient
was neutropenic and presented two positive GMI tests; four days
after the first positive GMI blood culture became positive for F.
verticillioides. In vitro this isolate tested positive for GMI, as did two
other isolates [10].
Our study differs from these two papers for the highest number
of patients, the different species distribution, and because we were
able to analyze both the temporal relationship between GMI
positivity and the diagnosis of invasive fusariosis, and the kinetics
of GMI related to the outcome. We found that the majority of
patients with invasive fusariosis presented with positive GMI. This
is of great importance in regions where invasive fusariosis is
frequent [16]. Among the three patients with negative GMI tests,
one was receiving voriconazole for almost one month before the
diagnosis of invasive fusariosis. Likewise, the two patients with
positive GMI tests 39 and 25 days before the diagnosis were
receiving anti-mould antifungal agents. This could have rendered
the test negative, by decreasing the sensitivity of GMI [17–19].
We also observed that not only GMI was frequently positive but
the number of positive tests (median of 4) and GMI values (peak
value as high as 6.382) were high. These data indicate that neither
the number of positive tests nor the actual GMI value is useful to
discriminate between invasive fusariosis and invasive aspergillosis.
Instead, other parameters should be taken into account, such as
the presence of metastatic skin lesions and positive blood cultures,
which are far more common in invasive fusariosis [20].
Invasive fusariosis is a devastating disease, with high mortality
rate, especially when the disease is disseminated, with various
metastatic skin lesions and lung involvement [21]. Although the
outcome is largely influenced by immune status of the host [22],
much of its poor prognosis may be related to the fact that fungal
burden is very high when the diagnosis is established. With this
regard, the use of a serum biomarker that allows clinicians to early
start antifungal treatment may have a potential benefit. This is
what has been observed with invasive aspergillosis [4,23,24]. In the
present study we observed that GMI was positive before the
diagnosis of invasive fusariosis in 73% of the 15 cases in which
GMI was positive, at a median of 10 days, and even before the first
clinical manifestation attributed to fusariosis in 53%. Furthermore,
seven of these 11 patients had at least two positive GMI tests
before the diagnosis ($4 tests in 5 patients). These data suggest
that if an antifungal agent active against Fusarium spp. is started as
a strategy of pre-emptive (or diagnostic-driven) approach based on
positive GMI tests [25], the disease can be treated earlier, with a
potential to improve the outcome.
In the present study the fastest way of reaching the diagnosis of
invasive fusariosis was by direct exam of biological materials
(especially skin biopsy), with the finding of hyaline hyphae
obtained just a few hours after the diagnostic procedure. Clinicians
should be very aggressive in promptly performing biopsy in the
presence of suspicious skin lesions, and appropriately handle the
biologic material, sending part of the biopsy for direct exam and
culture, and part for histopathology.
The kinetics of GMI after treatment has been increasingly
reported as an important tool to assess outcome, with better
survival in patients who have rapid normalization of GMI [26–
31]. In the present study we could not establish any correlation
between the kinetics of GMI and the outcome, with 37.5% of
patients who had normalization of GMI surviving 90 days after the
diagnosis of invasive fusariosis, compared with 29% of those who
did not normalize GMI. Reasons for not observing any correlation
may be due to the strong influence of host factors on the outcome
of invasive fusariosis [22], and the small number of patients
analyzed.
Our study has important implications for clinical practice.
Positive GMI tests in high-risk patients should be interpreted as
indicative of invasive aspergillosis and invasive fusariosis, especially
in centers/regions in which invasive fusariosis is more prevalent.
Likewise, a strategy of initiation of an antifungal agent based on
positive GMI and its ability to abort the overt clinical manifes-
tations of invasive fusariosis should be explored.
In conclusion, we showed that the majority of patients with
invasive fusariosis have positive GMI tests, and the test becomes
positive before the diagnosis of fusariosis in most cases.
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